An Early Phase 1 interventional study of Matrix Metalloproteinase Inhibitors (Orochem) and Kenacort A, in Oral Lichen Planus, sponsored by Jaylane kadry Ghonima. Status unknown at 1 site in Egypt. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2020-06-19.
Sponsored by Jaylane kadry Ghonima · Early Phase 1, Interventional, and Treatment
The current study will be conducted to evaluate the effectiveness of matrix metalloproteinases inhibitors on erosive oral lichen planus.
Matrix metalloproteinases inhibitor (Orochem) will be given to patients with Oral erosive lichen planus three times daily for 3 weeks. Then the subjective discomfort and pain severity as well as the objective disease severity scores will be collected.
139 studies on the registry are indexed under Lichen Planus, Oral; 24 are open to participants now.
This study's planned enrollment of 40 is above the median of 36 across 101 interventional studies indexed under Lichen Planus, Oral.
Browse Lichen Planus, Oral studies →This is the only study on the registry with Jaylane kadry Ghonima as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
fifteen patients with lichen planus will be treated with MMPs neutralizing agent 3 times daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
Drug: Matrix Metalloproteinase Inhibitors (Orochem)
fifteen patients with oral lichen planus confirmed with a biopsy will be treated with topical corticosteroids, topical antifungal 3 timed daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
Drug: Kenacort A,
topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus
topical application of both drugs 3 times daily for 3 weeks as an active control
Also known as: miconaz gel
change in disease severity score
Thongprasom disease severity score (5-0)
Time frame: change in disease severity score from baseline to 3 weeks
Plan to share: No — participants data are not to be shared
No publications or documents are linked to this record.
This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.